18
Participants
Start Date
May 6, 2025
Primary Completion Date
April 30, 2028
Study Completion Date
May 31, 2028
vvDD-hIL-2-RG-1
"A single dose of the investigational agent will be injected intratumorally at one of the following three dose levels.~Level 1: 3 x 108 p.f.u. Level 2: 1 x 109 p.f.u. Level 3: 3 x 109 p.f.u. p.f.u = Plaque-forming unit(s)~Dose will be escalated in cohorts of 3, according to a standard 3+3 design."
RECRUITING
AHN West Penn Hospital, Pittsburgh
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
OTHER